Compare GRBK & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRBK | NUVB |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.9B |
| IPO Year | N/A | N/A |
| Metric | GRBK | NUVB |
|---|---|---|
| Price | $66.68 | $8.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $71.00 | $10.63 |
| AVG Volume (30 Days) | 240.4K | ★ 10.3M |
| Earning Date | 10-29-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.63 | N/A |
| Revenue | ★ $2,113,173,000.00 | $26,748,000.00 |
| Revenue This Year | N/A | $609.55 |
| Revenue Next Year | $0.98 | $197.91 |
| P/E Ratio | $8.78 | ★ N/A |
| Revenue Growth | 6.62 | ★ 1137.19 |
| 52 Week Low | $50.57 | $1.54 |
| 52 Week High | $77.93 | $8.95 |
| Indicator | GRBK | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 68.86 |
| Support Level | $63.63 | $7.80 |
| Resistance Level | $68.19 | $8.95 |
| Average True Range (ATR) | 1.81 | 0.51 |
| MACD | 0.18 | -0.04 |
| Stochastic Oscillator | 59.96 | 77.09 |
Green Brick Partners Inc is a homebuilding and land development company. It acquires and develops land, as well as provides land and construction financing to its controlled builders. The company has three reportable segments: builder operations central, builder operations southeast, and land development. The majority of the company's revenue is generated from the builder operations central segment which is entirely the operations of builders in Texas. The company is engaged in various aspects of the homebuilding process, including land acquisition and development, entitlements, design, construction, marketing, sales, and brand image creation. In addition to homebuilding, the company provides home financing services, such as mortgage and title.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.